FDA Denies Expanded Use of Vascepa

Oct 18, 2013


Amarin Corporation's triglyceride-lowering drug Vascepa will not be approved for use in a broader patient population until results from an additional study have been analyzed, according to an advisory panel to the U.S. FDA. The panel voted 9-2 against approval of the drug for patients who also take a cholesterol-lowering statin such as Pfizer Inc.'s Lipitor and are at high risk of coronary heart disease. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments